Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Otenaproxesul

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance
    Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance

    02 Apr 2024

    // FINANCIAL TIMES

    https://markets.ft.com/data/announce/full?dockey=600-202404010700BIZWIRE_USPRX____20240401_BW046957-1

    FINANCIAL TIMES
    02 Apr 2024
    Share Share
    Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting
    Antibe to Present Otenaproxesul PK/PD Results at the ASRA Pain Medicine Meeting

    20 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240320913781/en

    BUSINESSWIRE
    20 Mar 2024
    Share Share
    Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul
    Antibe Receives Approval to Initiate PK/PD Study of Otenaproxesul

    28 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230928171285/en

    BUSINESSWIRE
    28 Sep 2023
    Share Share
    Antibe Provides Development Update for Otenaproxesul
    Antibe Provides Development Update for Otenaproxesul

    12 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221012005448/en

    BUSINESSWIRE
    12 Oct 2022
    Share Share
    Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022
    Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

    06 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220906005405/en

    BUSINESSWIRE
    06 Sep 2022
    Share Share
    Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
    Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results

    15 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220815005193/en

    BUSINESSWIRE
    15 Aug 2022
    Share Share